Considering that TAS-102 + Bev is used as a salvage option in metastatic CRC and can be recommended with other options such as regorafenib or capecitabine, selecting patients who would benefit more from TAS-102 + Bev through codon-specific KRAS mutation analysis would be highly advantageous in clinical practice. Here, KRAS is linked to colorectal carcinoma.